We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.
Enterprise Therapeutics – Acquisition to further develop the TMEM16A potentiator for the treatment of cystic fibrosis and potentially other severe respiratory diseases.
Pieris Pharmaceuticals – Research collaboration and license agreement to discover, develop and commercialize locally delivered respiratory therapies.
Novome Biotechnologies – Strategic collaboration and licensing agreement to discover, engineer and develop bacterial strains that express and deliver specific therapeutically relevant molecules to targets in the human intestinal tract to treat diseases such as IBD.
Enza di Modugno, Head of Immunology & Infectious Diseases, Pharma Partnering
Jean-Eric Charoin, Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering